cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Novo's disappoint analysts, sending stock tumbling - MM+M After CagriSema blow, Novo reveals
After CagriSema blow, Novo reveals data for obesity 'triple' pharmaphorum Incretin based therapies for the treatment of obesity related diseases npj Metabolic Health and Disease Novo's CagriSema loses phase 3 obesity battle against Zepbound Novo Nordisk's CagriSema 2.4 mg 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 CAGRISEMA: The Latest Breakthrough in Weight Loss Medication
Pay in 4 interest-free payments of $6.25 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8




